About Aduro BioTech (NASDAQ:ADRO)
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400
Debt
Debt-to-Equity RatioN/A
Current Ratio8.46%
Quick Ratio8.46%
Price-To-Earnings
Trailing P/E Ratio-4.89
Forward P/E Ratio-5.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.24 million
Price / Sales32.66
Cash FlowN/A
Price / CashN/A
Book Value$3.07 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-91,860,000.00
Net Margins-532.88%
Return on Equity-37.86%
Return on Assets-20.52%
Miscellaneous
Employees162
Outstanding Shares81,010,000
Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions
What is Aduro BioTech's stock symbol?
Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."
How were Aduro BioTech's earnings last quarter?
Aduro BioTech Inc (NASDAQ:ADRO) posted its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.01. The biotechnology company had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.32 million. Aduro BioTech had a negative return on equity of 37.86% and a negative net margin of 532.88%. View Aduro BioTech's Earnings History.
What price target have analysts set for ADRO?
8 brokerages have issued 1-year price objectives for Aduro BioTech's shares. Their predictions range from $8.00 to $30.00. On average, they anticipate Aduro BioTech's stock price to reach $15.6667 in the next year. View Analyst Ratings for Aduro BioTech.
What are Wall Street analysts saying about Aduro BioTech stock?
Here are some recent quotes from research analysts about Aduro BioTech stock:
- 1. According to Zacks Investment Research, "Aduro reported narrower-than-expected loss in the fourth quarter of 2017 while revenues missed estimates. The company has a broad, promising pipeline of novel immunotherapies under development for treatment of a variety of cancers. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate the company’s research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry in a year’s time." (3/7/2018)
- 2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)
- 3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)
- 4. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
Who are some of Aduro BioTech's key competitors?
Some companies that are related to Aduro BioTech include Epizyme (EPZM), TG Therapeutics (TGTX), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Athenex (ATNX), Zai Lab (ZLAB), CytomX Therapeutics (CTMX), Uniqure (QURE), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Access Pharmaceuticals (ABEO), Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN) and Inflarx (IFRX).
Who are Aduro BioTech's key executives?
Aduro BioTech's management team includes the folowing people:
- Mr. Stephen T. Isaacs, Chairman, Pres & CEO (Age 69)
- Mr. Blaine E. Templeman, Chief Legal Officer & Sec. (Age 52)
- Dr. Natalie R. Sacks M.D., Chief Medical Officer (Age 53)
- Ms. Jennifer Lew, Chief Financial Officer (Age 45)
- Mr. Gregory W. Schafer, Consultant (Age 54)
When did Aduro BioTech IPO?
(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Has Aduro BioTech been receiving favorable news coverage?
News articles about ADRO stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aduro BioTech earned a news impact score of 0.21 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Aduro BioTech?
Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aduro BioTech's stock price today?
One share of ADRO stock can currently be purchased for approximately $6.95.
How big of a company is Aduro BioTech?
Aduro BioTech has a market capitalization of $575.15 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.
How can I contact Aduro BioTech?
Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]
MarketBeat Community Rating for Aduro BioTech (ADRO)
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aduro BioTech (NASDAQ:ADRO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Aduro BioTech in the last 12 months. Their average twelve-month price target is $15.6667, suggesting that the stock has a possible upside of 125.42%. The high price target for ADRO is $30.00 and the low price target for ADRO is $8.00. There are currently 1 sell rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 3.00 | 3.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.6667 | $15.6667 | $18.50 | $20.00 |
| Price Target Upside: | 125.42% upside | 132.10% upside | 158.74% upside | 110.53% upside |
Aduro BioTech (NASDAQ:ADRO) Consensus Price Target History
Aduro BioTech (NASDAQ:ADRO) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Aduro BioTech (NASDAQ:ADRO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aduro BioTech (NASDAQ ADRO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 44.91%
Aduro BioTech (NASDAQ ADRO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Stephen T Isaacs | Insider | Sell | 40,000 | $8.91 | $356,400.00 | 245,746 |  |
| 3/9/2018 | Stephen T Isaacs | Insider | Sell | 72,051 | $8.48 | $610,992.48 | 231,380 | |
| 2/26/2018 | Elsas Andrea Van | Insider | Sell | 6,874 | $6.48 | $44,543.52 | 216,669 | |
| 1/5/2018 | Stephen T Isaacs | Insider | Sell | 7,949 | $7.95 | $63,194.55 | 213,695 | |
| 1/2/2018 | Gregory W Schafer | COO | Sell | 20,000 | $7.61 | $152,200.00 | 190,745 | |
| 12/18/2017 | Blaine Templeman | VP | Sell | 2,884 | $8.25 | $23,793.00 | 69,937 | |
| 12/15/2017 | Dirk G Brockstedt | EVP | Sell | 65,223 | $8.11 | $528,958.53 | 137,826 | |
| 12/1/2017 | Dirk G Brockstedt | EVP | Sell | 10,000 | $9.40 | $94,000.00 | 77,674 | |
| 12/1/2017 | Gregory W Schafer | COO | Sell | 20,000 | $9.34 | $186,800.00 | 155,676 | |
| 12/1/2017 | Jennifer Lew | VP | Sell | 6,600 | $9.46 | $62,436.00 | 68,938 | |
| 12/1/2017 | Stephen T Isaacs | Insider | Sell | 40,000 | $9.38 | $375,200.00 | 213,921 | |
| 11/17/2017 | Blaine Templeman | VP | Sell | 243 | $8.85 | $2,150.55 | | |
| 11/15/2017 | Jennifer Lew | Insider | Sell | 6,600 | $8.95 | $59,070.00 | 68,938 | |
| 11/13/2017 | Dirk G Brockstedt | EVP | Sell | 5,877 | $8.00 | $47,016.00 | 75,533 | |
| 11/13/2017 | Stephen T Isaacs | Insider | Sell | 19,800 | $7.97 | $157,806.00 | 190,321 | |
| 11/10/2017 | Dirk G Brockstedt | EVP | Sell | 1,815 | $8.01 | $14,538.15 | 75,533 | |
| 11/10/2017 | Stephen T Isaacs | CEO | Sell | 16,400 | $7.96 | $130,544.00 | 190,321 | |
| 11/7/2017 | Stephen T Isaacs | Insider | Sell | 20,200 | $7.98 | $161,196.00 | 190,321 | |
| 11/6/2017 | Dirk G Brockstedt | EVP | Sell | 4,123 | $8.04 | $33,148.92 | 77,841 | |
| 11/6/2017 | Gregory W Schafer | COO | Sell | 20,000 | $7.97 | $159,400.00 | 155,677 | |
| 10/2/2017 | Dirk G Brockstedt | EVP | Sell | 10,000 | $10.59 | $105,900.00 | | |
| 10/2/2017 | Gregory W Schafer | COO | Sell | 20,000 | $10.75 | $215,000.00 | | |
| 10/2/2017 | Jennifer Lew | Insider | Sell | 6,600 | $10.61 | $70,026.00 | | |
| 10/2/2017 | Stephen T Isaacs | CEO | Sell | 40,000 | $10.78 | $431,200.00 | 213,921 | |
| 9/18/2017 | Blaine Templeman | VP | Sell | 2,884 | $11.20 | $32,300.80 | 58,834 | |
| 9/13/2017 | Blaine Templeman | VP | Sell | 3,557 | $10.99 | $39,091.43 | 65,275 | |
| 9/13/2017 | Elsas Andrea Van | Insider | Sell | 4,922 | $10.99 | $54,092.78 | 212,153 | |
| 9/13/2017 | Gregory W Schafer | COO | Sell | 4,859 | $10.99 | $53,400.41 | 153,604 | |
| 9/1/2017 | Dirk G Brockstedt | EVP | Sell | 10,000 | $11.69 | $116,900.00 | 59,300 | |
| 9/1/2017 | Gregory W Schafer | COO | Sell | 20,000 | $11.70 | $234,000.00 | 131,645 | |
| 9/1/2017 | Jennifer Lew | Insider | Sell | 6,600 | $11.70 | $77,220.00 | 49,195 | |
| 8/11/2017 | Thomas W Dubensky | Insider | Sell | 50,000 | $11.38 | $569,000.00 | 80,812 | |
| 8/10/2017 | Thomas W Dubensky | Insider | Sell | 40,912 | $11.43 | $467,624.16 | 80,812 | |
| 8/8/2017 | Gregory W Schafer | COO | Sell | 40,000 | $12.17 | $486,800.00 | 133,879 | |
| 8/7/2017 | Dirk G Brockstedt | EVP | Sell | 10,000 | $12.18 | $121,800.00 | 59,300 | |
| 8/7/2017 | Gregory W Schafer | COO | Sell | 25,811 | $12.17 | $314,119.87 | 133,879 | |
| 8/7/2017 | Jennifer Lew | Insider | Sell | 6,600 | $12.17 | $80,322.00 | 49,195 | |
| 8/7/2017 | Stephen T Isaacs | CEO | Sell | 40,000 | $12.19 | $487,600.00 | 144,025 | |
| 7/6/2017 | Thomas W Dubensky | Insider | Sell | 50,000 | $11.33 | $566,500.00 | 51,700 | |
| 7/5/2017 | Stephen T Isaacs | Insider | Sell | 40,000 | $11.06 | $442,400.00 | 132,093 | |
| 7/3/2017 | Dirk G Brockstedt | EVP | Sell | 10,000 | $11.02 | $110,200.00 | 53,956 | |
| 7/3/2017 | Jennifer Lew | Insider | Sell | 12,000 | $11.14 | $133,680.00 | 54,595 | |
| 6/28/2017 | Gregory W Schafer | COO | Sell | 40,000 | $11.26 | $450,400.00 | 160,979 | |
| 6/28/2017 | Jennifer Lew | Insider | Sell | 12,000 | $11.19 | $134,280.00 | 54,595 | |
| 6/19/2017 | Stephen T Isaacs | Insider | Sell | 40,000 | $10.50 | $420,000.00 | 125,486 | |
| 6/5/2017 | Thomas W Dubensky | Insider | Sell | 144,301 | $10.03 | $1,447,339.03 | 117,871 | |
| 5/17/2017 | Blaine Templeman | VP | Sell | 1,648 | $9.65 | $15,903.20 | | |
| 5/17/2017 | Dirk G. Brockstedt | EVP | Sell | 1,011 | $9.65 | $9,756.15 | | |
| 5/16/2017 | Stephen T. Isaacs | CEO | Sell | 16,673 | $10.00 | $166,730.00 | | |
| 5/16/2017 | Stephen T. Isaacs | insider | Sell | 27,273 | $10.01 | $273,002.73 | | |
| 5/15/2017 | Stephen T. Isaacs | CEO | Sell | 10,600 | $10.01 | $106,106.00 | | |
| 5/12/2017 | Thomas W Dubensky | Insider | Sell | 5,699 | $9.92 | $56,534.08 | 41,300 | |
| 5/11/2017 | Dirk G Brockstedt | EVP | Sell | 8,000 | $9.72 | $77,760.00 | 57,300 | |
| 4/3/2017 | Dirk G Brockstedt | EVP | Sell | 8,000 | $10.71 | $85,680.00 | 57,300 | |
| 4/3/2017 | Stephen T Isaacs | Insider | Sell | 27,273 | $10.28 | $280,366.44 | 129,473 | |
| 3/13/2017 | Stephen T Isaacs | Insider | Sell | 27,273 | $11.35 | $309,548.55 | 129,473 | |
| 3/9/2017 | Dirk G Brockstedt | EVP | Sell | 8,000 | $11.00 | $88,000.00 | 57,300 | |
| 3/9/2017 | Thomas W Dubensky | Insider | Sell | 25,000 | $10.96 | $274,000.00 | 54,804 | |
| 1/17/2017 | Dirk G Brockstedt | EVP | Sell | 8,000 | $11.86 | $94,880.00 | 57,300 | |
| 1/11/2017 | Blaine Templeman | VP | Sell | 3,785 | $11.95 | $45,230.75 | | |
| 1/3/2017 | Stephen T Isaacs | Insider | Sell | 27,273 | $11.12 | $303,275.76 | 119,896 | |
| 12/1/2016 | Thomas W Dubensky | Insider | Sell | 25,000 | $10.94 | $273,500.00 | 53,763 | |
| 11/14/2016 | Ross Haghighat | Director | Sell | 7,088 | $15.50 | $109,864.00 | | |
| 10/3/2016 | Stephen T Isaacs | CEO | Sell | 27,273 | $12.67 | $345,548.91 | 129,473 | |
| 10/3/2016 | Thomas W Dubensky | Insider | Sell | 25,000 | $12.68 | $317,000.00 | 55,424 | |
| 9/19/2016 | Jennifer Lew | Insider | Sell | 6,360 | $14.95 | $95,082.00 | 48,955 | |
| 9/1/2016 | Thomas W Dubensky | Insider | Sell | 25,000 | $14.03 | $350,750.00 | 16,407 | |
| 8/11/2016 | Thomas W Dubensky | Insider | Sell | 25,000 | $15.18 | $379,500.00 | 12,500 | |
| 7/5/2016 | Thomas W Dubensky | Insider | Sell | 25,000 | $11.61 | $290,250.00 | 13,939 | |
| 5/16/2016 | Thomas W. Dubensky | Insider | Sell | 905 | $8.20 | $7,421.00 | | |
| 1/11/2016 | Dirk G. Brockstedt | VP | Sell | 22,000 | $21.77 | $478,940.00 | 12,000 | |
| 1/8/2016 | Gregory W. Schafer | COO | Sell | 20,000 | $23.58 | $471,600.00 | 49,279 | |
| 1/6/2016 | Jennifer Lew | VP | Sell | 5,242 | $25.71 | $134,771.82 | 6,200 | |
| 1/5/2016 | Stephen T. Isaacs | CEO | Sell | 25,000 | $26.31 | $657,750.00 | 10,000 | |
| 1/4/2016 | Thomas W. Dubensky | insider | Sell | 15,000 | $26.37 | $395,550.00 | | |
| 12/7/2015 | Gregory W. Schafer | COO | Sell | 25,000 | $29.74 | $743,500.00 | 34,279 | |
| 12/3/2015 | Jennifer Lew | VP | Sell | 5,242 | $29.85 | $156,473.70 | 2,000 | |
| 12/1/2015 | Stephen T. Isaacs | CEO | Sell | 25,000 | $29.11 | $727,750.00 | | |
| 12/1/2015 | Thomas W. Dubensky | insider | Sell | 30,000 | $29.27 | $878,100.00 | | |
| 11/18/2015 | Jennifer Lew | VP | Sell | 6,712 | $28.52 | $191,426.24 | 2,000 | |
| 11/17/2015 | Gregory W. Schafer | COO | Sell | 26,470 | $28.15 | $745,130.50 | 34,279 | |
| 11/17/2015 | Thomas W. Dubensky | insider | Sell | 31,470 | $28.27 | $889,656.90 | | |
| 11/16/2015 | Stephen T. Isaacs | CEO | Sell | 25,000 | $27.54 | $688,500.00 | | |
| 4/20/2015 | Jennifer Lew | VP | Buy | 2,000 | $17.00 | $34,000.00 | | |
| 4/20/2015 | Venture (Vi) Inves Morningside | Major Shareholder | Buy | 441,176 | $17.00 | $7,499,992.00 | | |
| 4/20/2015 | William Mariner Greenman | Director | Buy | 3,000 | $17.00 | $51,000.00 | | |
(Data available from 1/1/2013 forward)
Aduro BioTech (NASDAQ ADRO) News Headlines
| Source: |
|
Aduro BioTech (NASDAQ:ADRO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aduro BioTech (NASDAQ:ADRO) Income Statement, Balance Sheet and Cash Flow Statement
Aduro BioTech (NASDAQ ADRO) Stock Chart for Saturday, April, 21, 2018
Loading chart…
